

# NEWFOUNDLAND AND LABRADOR PHARMACY BOARD



## PROVINCIAL DRUG SCHEDULES

Under and by virtue of the powers contained in the Pharmacy Act and section 45 of the Pharmaceutical Association Regulations, 1998, the Minister, upon the recommendation of the Newfoundland and Labrador Pharmacy Board, approves the following schedules of drugs.

*Approved May 23, 2011*

**TABLE OF CONTENTS**

Schedule I .....	3
Schedule II .....	6
Schedule III .....	11
Unscheduled .....	14

## SCHEDULE I

The drugs listed in Schedule I require a prescription for sale and are provided to the public following the diagnosis and professional intervention of a practitioner. They are subject to the same regulations as the drugs listed in Part II to Schedule "F" of the Food and Drug Regulations (Canada) (Sections C.01.001, C.01.041 to C.01.047).

Note: All drugs that require a prescription in accordance with Canadian federal regulations (*Food and Drugs Regulations* and *Regulations to the Controlled Drugs and Substances Act*), or are designated as "Schedule F Recommended" or "[CDSA Recommended](#)" by Health Canada, are [considered](#) Schedule I drugs under these regulations, notwithstanding the fact that they are not specifically listed in Schedule I. **Items in BOLD UNDERLINE** are changes from the previous versions.

### DRUG NAME

allergy serums and extracts

alpha 1-proteinase inhibitor (human)

alverine and its salts for parenteral use

amino acid solutions for parenteral use

aminopromazine [proquamezine] and its salts

bacillus Calmette-Guerin vaccine

bacitracin and its salts and derivatives for parenteral use

calcium chloride in injectable form for parenteral nutrition

calcium gluconate in injectable form for parenteral nutrition

cetirizine and its salts when sold in concentrations greater than 8.5 mg cetirizine base per dosage unit

cholera vaccine except oral, inactivated, when used for prophylaxis against Traveler's Diarrhea due to enterotoxigenic escherichia coli [ETEC]

chromium chloride (chromic chloride) in injectable form for parenteral nutrition

cimetidine and its salts in concentrations greater than 100mg of cimetidine per dosage unit

clotrimazole and its salts (except in preparations for topical or vaginal use)

copper chloride (cupric chloride) in injectable form for parenteral nutrition

copper sulphate in injectable form for parenteral nutrition

cromoglycic acid and its salts (except sodium cromoglycate in solutions for ophthalmic or nasal use in concentrations of 2% or less)

cyclopentolate and its salts in preparations for parenteral or ophthalmic use (except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada)

cytomegalovirus immune globulins

dextrose injection in concentrate solutions for parenteral nutrition

diiodohydroxyquin (except in preparations for topical use on the skin)

encephalitis vaccine (Japanese)

ephedrine and its salts in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion

epinephrine and its salts other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens

erythrityl tetranitrate

ethylpapaverine and its salts

famotidine and its salts (except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn)

fluconazole (except when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis)

flumazenil

fluoride and its salts (see sodium fluoride) in solid oral dosage forms containing more than 1 mg of fluoride ion

folic acid in preparations containing more than 1 mg of folic acid per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1.0 mg folic acid

hepatitis A vaccine

hepatitis B adult vaccine

hepatitis B immune globulin

homatropine and its salts for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit

## DRUG NAME

hydrocortisone (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

hydrocortisone acetate (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

iodochlorohydroxyquin (except in preparations for topical use on the skin)

isopropamide and its salts

isosorbide and its salts

ketoconazole and its salts (except in preparations for topical use as a shampoo)

levallorphan and its salts

lipid solutions in injectable form for parenteral nutrition

Lyme Disease vaccine

magnesium sulphate in injectable form for parenteral nutrition

manganese and its salts in injectable form for parenteral nutrition

meclizine and its salts when sold in concentrations greater than 25mg per dosage unit

metaraminol bitartrate

methacholine and its salts

miconazole and its salts (except in preparations for topical or vaginal use)

minoxidil (except in solutions for topical use in concentrations of 2% or less)

mupirocin

naproxen and its salts (with the exception of naproxen sodium 220 mg per [oral dosage unit](#))

nicotine and its salts, for human use (except: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; or (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit); or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit.)

nicotinic acid when sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose

nicotiny-tartrate

nikethamide

nitroglycerin (except for sublingual immediate release dosage forms)

nizatidine and its salts (except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine)

nystatin and its salts and derivatives (except preparations for topical use on the skin)

orphenadrine hydrochloride

pancreatic enzymes in products for the treatment of established pancreatic insufficiency

pancreatin in products for the treatment of established pancreatic insufficiency

pancrelipase in products for the treatment of established pancreatic insufficiency

papavertrine and its salts

papaverine and its salts

pentaerythritol tetranitrate

phenylephrine and its salts in preparations for parenteral use or ophthalmic use in concentrations greater than 2.5%

physostigmine salicylate (except preparations for oral or topical use only)

polymyxin B and its salts and derivatives (except for topical use or for local action in the oral cavity or nasal passages)

potassium para-aminobenzoate (except in preparations for topical use on the skin)

potassium salts in preparations for injection

proquamezine [aminopromazine] and its salts for internal use

quinidine salts

rabies immune globulin

rabies vaccine

ranitidine and its salts (except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn)

rho D immune globulin

selenium in injectable form for parenteral nutrition

sodium acetate in injectable form for parenteral nutrition

sodium chloride in injectable form for parenteral nutrition

sodium iodine in injectable form for parenteral nutrition

## DRUG NAME

sodium phosphate in injectable form for parenteral nutrition

ticlozazole and its salts (except in preparations for topical or vaginal use in humans)

tetanus immune globulin

tropicamide and its salts in preparations for parenteral or ophthalmic use (except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada)

tubocurarine and its salts

typhoid vaccines/Salmonella Typhi vaccines

vaccines (except for - those which are part of a routine immunization program in most/all provinces & territories: cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); diphtheria toxoid, haemophilus influenzae type b, hepatitis B pediatric, influenza, measles, mumps, pertussis, pneumococcus, poliomyelitis, rubella, tetanus toxoid; and - those requiring special enhanced public access due to disease outbreaks: meningococcus)

varicella vaccine (chicken pox)

varicella zoster immune globulin

vitamin A in oral dosage forms containing more than 10,000 IU per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 IU of Vitamin A

vitamin D in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by the person of more than 1,000 International Units of Vitamin D

vitamin K (except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less)

vitamins in injectable form for parenteral nutrition

yellow fever vaccine

zinc chloride in injectable form for parenteral nutrition

zinc sulphate in injectable form for parenteral nutrition

**Pharmacists are reminded that all drugs specified in the Schedule of Drugs associated with the "Tamper Resistant Prescription Drug Pad Program" must be prescribed using the tamper resistant drug pad. This list can be found on the Department of Health and Community Services website at the following link:**  
**[http://www.health.gov.nl.ca/health/prescription/hcp\\_tamperresistantdrugpad.html#sched1](http://www.health.gov.nl.ca/health/prescription/hcp_tamperresistantdrugpad.html#sched1)**

## SCHEDULE II

The drugs listed in Schedule II require the professional intervention of a pharmacist at the point of sale and possible referral to a practitioner. A prescription is not required for the drugs listed on this schedule but the drugs are available only from the pharmacist and shall be retained within an area of the pharmacy where there is no public access and no opportunity for patient self-selection. **Items in BOLD UNDERLINE are changes from the previous versions.**

### DRUG NAME

acetarsol  
acetylcysteine  
acetylsalicylic acid (ASA) and its salts (in oral preparations containing 80 mg or less per dosage unit and intended for pediatric use OR rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid)  
adiphen and its salts for parenteral use  
allethrins  
amylocaine and its salts (for ophthalmic or parenteral use)  
anisotropine and its salts  
anthralin  
antihemophilic factor, human  
antipyrine (except otic preparations)  
apomorphine and its salts  
arginine and its salts  
artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic preparations)

belladonna alkaloids and their salts and derivatives (except in preparations for topical use or in trace amounts in homeopathic preparations)  
benoxinate hydrochloride (oxybuprocaine) for ophthalmic or parenteral use  
bentiromide  
benzalkonium and its salts (liquid preparations in concentrations greater than 2%)  
benzethonium chloride (liquid preparations in concentrations greater than 1%)  
benzocaine and its salts (for ophthalmic or parenteral use)  
benzyl benzoate  
boric acid and its salts (in preparations for systemic or ophthalmic use in concentrations greater than 2%, except in contact lens solutions intended to be rinsed off prior to insertion in the eye.)  
buclizine  
bufexamac  
bupivacaine and its salts (for ophthalmic or parenteral use)  
butacaine and its salts (for ophthalmic or parenteral use)

calcium disodium edentate  
camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)  
cantharides, their preparations and derivatives  
charcoal (activated) for use in poisoning treatment  
chloroprocaine and its salts (for ophthalmic or parenteral use)  
cholecystokinin  
cholera vaccine (oral, inactivated) when used for prophylaxis against Traveler's Diarrhea due to enterotoxigenic escherichia coli [ETEC]  
choline bitartrate (for parenteral use)  
chymopapain (for parenteral use)  
chymotrypsin (for ophthalmic and parenteral use)  
cinchocaine (dibucaine) and its salts (for ophthalmic or parenteral use)  
clidinium and its salts  
clobetasone butyrate (when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)  
coal tar (in concentrations greater than 10%)  
codeine and its salts (in preparations exempted from the Regulations to the Controlled Drugs and Substances Act)  
collagenase (as a debriding agent)  
crotamiton  
cyclandelate  
cyclazocine and its salts  
cyclomethacaine and its salts (for ophthalmic or parenteral use)  
cyclopentamine and its salts  
cyclopentolate and its salts (except in products for ophthalmic or parenteral use)  
cyproheptadine and its salts

## DRUG NAME

desoxyribonuclease [pancreatic dornase]

dextrose (sclerosing agents)

dicyclomine and its salts (except for topical use and lozenges)

dihydroquinidine and its salts (except phenylbarbiturate)

diiodohydroxyquin (for topical use on the skin)

dimenhydrinate and its salts (for parenteral use)

diperodon and its salts (except for topical use)

diphenhydramine and its salts and preparations (for parenteral use)

diphenhydramine and its salts and preparations (for topical use in concentrations of greater than 2%)

diphtheria toxoid

dyclonine (except for topical use on mucous membranes)

ephedrine and its salts in single entity products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for not more than 7 days, and indicated for nasal congestion)

epinephrine and its salts (in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens.)

esdepallethrin/piperonyl butoxide

ethanolamine oleate

ethoheptazine and its salts

ethyl chloride (except in trace amounts)

fibrin

fibrinolysin

gentian violet (for application to skin or mucous membranes)

glucagon

glycopyrrolate and its salts

hemophilus influenzae type B vaccine

heparin and its salts (except for topical use)

hepatitis B pediatric vaccine

histamine and its salts (except for topical use)

homatropine and its salts (for oral use in concentrations of 2 mg or less per dosage unit)

human insulin

hyaluronic acid and its salts (preparations in concentration of 5% or more)

hyaluronidase

hydroquinone (topical preparations)

hydroxyephedrine and its salts

hyoscine and its salts and derivatives [scopolamine]

hyoscyamine and its salts and derivatives (except for topical use)

influenza vaccine

insulin

iodinated glycerol

iodine and its salts and derivatives (except in topical preparations or in oral doses of 1 mg or less per day)

iodochlorhydroxyquin (for topical use)

ipecac & its extracts & derivatives (when used as an emetic)

iron and its salts and derivatives (in preparations with more than 30mg elemental iron per unit or 5ml liquid)

levargorphane and its salts

levonordefrine

levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.))

lidocaine and its salts (for ophthalmic or parenteral use or topical use on mucous membranes except lozenges)

lindane

loperamide and its salts in products marketed for pediatric use – under 12 years of age

magnesium sulphate (for parenteral use)

mannitol and its salts

measles vaccine

meningococcus vaccine

mepivacaine and its salts (for ophthalmic or parenteral use)

metathoheptazine and its salts

## DRUG NAME

methantheline  
methdilazine and its salts  
methenamine and its salts (except for topical use)  
metheptazine and its salts  
methocarbamol (for parenteral use)  
methyl salicylate (in liquid dosage forms in concentrations greater than 30%)  
methylene blue (for parenteral use)  
monobenzene  
monoethanolamine oleate  
mumps vaccine  
  
naphazoline and its salts (in nasal preparations for pediatric use)  
~~naproxen sodium 220 mg per tablet (when sold in products labelled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6,600 mg)~~  
niacin [nicotinic acid] (in extended release formulations)  
nitroglycerin (sublingual immediate release dosage forms)  
norepinephrine and its salts [levarteronol, noradrenaline]  
  
oxymetazoline and its salts (in nasal preparations for pediatric use)  
oxyquinoline  
  
paroxypropione  
pentagastrin and its salts  
permethrin and its derivatives  
pertussis vaccine  
phenol (preparations with concentrations greater than 20%)  
phenoxybenzamine and its salts  
phenylephrine and its salts and preparations (in nasal preparations in concentrations of 2.5% or less for pediatric use)  
physostigmine salicylate (for oral or topical use)  
piperazine and its salts  
pneumococcal polysaccharide vaccine  
pneumococcal 7-valent conjugate vaccine  
poliomyelitis vaccine  
polyacrylamide  
potassium salts (in preparations containing greater than 5 mmol per dose)  
povidone-iodine (vaginal preparations, except in concentrations of 5 % or less)  
pramoxine and its salts (for ophthalmic or parenteral use)  
prilocaine and its salts (for ophthalmic or parenteral use)  
procaine and its salts (for ophthalmic or parenteral use)  
promethazine and its salts (except for topical use)  
proprantheline and its salts  
proparacaine and its salts (for ophthalmic or parenteral use)  
propylhexidine  
protamine and its salts  
pseudoephedrine and its salts and preparations in single entity products  
pyrantel and its salts  
pyrethrins  
pyrethrins/piperonyl butoxide  
pyrivinium and its salts  
  
racemethionine  
rose bengal  
rubella vaccine  
rue and its preparations and extracts  
  
salicylic acid and its salts (in topical preparations in concentrations greater than 40%)  
silver nitrate  
sincalide  
sodium acetate (for parenteral use)  
sodium biphosphate (for parenteral use)  
sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations greater than 0.9%) [Does not apply to contact lens products intended to be rinsed off prior to insertion in the eye.]  
sodium citrate (for parenteral use)

**DRUG NAME**

sodium iodide (for sclerosing)

sodium phosphate (for parenteral use)

sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5g and citric acid 12g)

sodium tetradecyl sulphate

stramonium, its preparations, extracts and compounds

streptokinase (as a debriding agent)

strontium and its salts (for parenteral use)

sutilains

tetanus toxoid

tetracaine and its salts (for ophthalmic and parenteral use)

tetrahydrozoline (in nasal preparations for pediatric use)

thrombin

thyroglobulin

thyrotropin

urea in topical preparations in concentrations greater than 25%

vitamins (any parenterals not included in Schedule I)

xylometazoline and its salts (in nasal preparations for pediatric use (0.05%))

xylose

### **SCHEDULE III**

The drugs listed in Schedule III may present risks to certain populations in self-selection and although available without a prescription, these drugs are to be sold from the self-selection area of a pharmacy which is operated under the direct supervision of a pharmacist. **Items in BOLD UNDERLINE are changes from the previous versions.**

#### **DRUG NAME**

acetaminophen in sustained release formulations (in strengths of greater than 650 mg per unit or in package sizes of more than 50 units)  
acetylsalicylic acid and its salts (in products intended for oral adult use in strengths of 81mg per dosage unit and 650mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit)  
aloe vera latex, its extracts and derivatives [except aloin] (dosage forms for systemic use containing more than 300 mg per dosage unit)  
aluminum oxide  
amylocaine and its salts (in preparations for topical use on mucous membranes except lozenges)  
anetholtrithione  
antazoline and its salts  
antipyrine (for otic use)

bacitracin and its salts and derivatives (for ophthalmic use)  
belladonna alkaloids, their salts and derivatives (for topical use)  
benzocaine and its salts (for topical use on mucous membranes for teething)  
benzonatate  
berberis vulgaris (Barberry)  
bisacodyl and its salts  
brompheniramine and its salts (as a single entity for the treatment of allergies)  
bupivacaine and its salts (for topical use on mucous membranes except lozenges)

calcium polycarbophil  
carbinoxamine and its salts  
casanthranol  
cerapon  
cetirizine and its salts (in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit in products marketed for pediatric use (under 12 years of age))  
chlorthalidone and its salts  
chlorprocaine and its salts (for topical use on mucous membranes except lozenges)  
chlorzoxazone and its salts  
cimetidine and its salts (in concentrations of 100 mg or less per dosage unit)  
clemastine and its salts  
clotrimazole and its salts (in preparations for intra-vaginal use)

danthron  
dehydrocholic acid and its salts  
deoxycholic acid and its salts  
desloratidine and its salts and preparations (in products marketed for pediatric use – under 12 years of age)  
dextbrompheniramine and its salts  
dexchlorpheniramine and its salts  
dextromethorphan and its salts  
dimenhydrinate and its salts (for oral or rectal use) [Note: Pharmacists are advised that in areas where there is evidence of abuse or a particular concern about abuse, dimenhydrinate products should not be located in a self-selection area of the pharmacy]  
dimethothiazine  
diphenhydramine and its salts and preparations (except for parenteral use)  
diphenhydramine and its salts and preparations for topical use in concentrations of 2% or less when sold in containers of greater than 300 mg of diphenhydramine hydrochloride  
diphenylpyraline  
doxylamine and its salts (except those sold for nausea and vomiting of pregnancy)  
dyclonine and its salts (for topical use on mucous membranes except lozenges)

electrolyte solutions (for oral rehydration)  
ephedrine and its salts in combination products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for not more than 7 days, and indicated for nasal congestion) [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, ephedrine products should NOT be located in a self-selection area of the pharmacy]

## DRUG NAME

famotidine and its salts, when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine

fexofenadine hydrochloride (in products marketed for paediatric use (under 12 years of age))

fluconazole when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole

fluoride and its salts (see sodium fluoride) (oral preparations containing 1 mg or less of fluoride ion per dosage unit)

fractar

glyceroargentate

gramicidin and its salts and derivatives (for ophthalmic use)

haloproglin

heparin and its salts (for topical use)

hydrocortisone acetate (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

hydrocortisone (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

iodine and its salts and derivatives (for topical use)

isopropyl myristate in concentration of 50% (for use in the treatment of head lice)

lactic acid (in preparations in concentrations of more than 10%)

lactulose

levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel)

lidocaine and its salts (for otic use)

lidocaine and prilocaine (eutectic mixture)

loratadine and its salts and preparations in products marketed for pediatric use (under 12 years of age)

magnesium citrate (cathartics)

magnesium salicylate (except oral dosage forms which also contain choline salicylate)

meclizine and its salts (when sold in concentrations of 25mg or less per dosage unit)

mepivacaine and its salts (for topical use on mucous membranes except lozenges)

methocarbamol (except for parenteral use)

miconazole and its salts (for vaginal use)

mineral tar (except shampoos with concentrations less than 5%)

minoxidil (for topical use in concentrations of 2% or less)

[naproxen sodium 220 mg per oral dosage unit \(when sold in products labelled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6,600 mg\)](#)

~~[naproxen sodium 220 mg tablet \(when sold in products labelled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6,600 mg\)](#)~~

narcotine and its salts (noscapine)

nystatin and its salts and derivatives (in topical preparations for use on the skin)

orphenadrine citrate

oxethazine

oxybuprocaine and its salts (for topical use on mucous membranes except lozenges)

phenyltoloxamine and its salts

polymyxin B and its salts and derivatives (for ophthalmic use)

povidone - iodine (in topical preparations, except in concentrations of 5% or less)

pramoxine and its salts (for topical use on mucous membranes except lozenges)

prilocaine and its salts (for topical use on mucous membranes except lozenges)

procaine and its salts (for topical use on mucous membranes except lozenges)

promethazine and its salts (for topical use)

proparacaine and its salts (for topical use on mucous membranes except lozenges)

pseudoephedrine and its salts and preparations in combination products [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should NOT be located in a self-selection area of the pharmacy]

ranitidine and its salts, when sold in concentrations of 150mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500mg of ranitidine

**DRUG NAME**

sodium biphosphate (cathartics)

sodium cromoglycate (in solutions in concentrations of 2% or less for ophthalmic or nasal use)

sodium phosphate (cathartics)

tetracaine and its salts (for topical use on mucous membranes except lozenges)

tioconazole and its salts (in preparations for vaginal use)

triethanolamine oleate

triethanolamine salicylate (in concentrations greater than 20%)

tripelennamine and its salts

triprolidine

tyrothricine

vegetable tar (except shampoos in concentrations of 5% or less)

## UNSCHEDULED

Many drugs have been reviewed by NDSAC but have not been assigned any place in the above schedules. Also, many drugs that are included in the schedules are included based on specific parameters such as strength and dosage form. That same drug in another strength or dosage form may be considered "Unscheduled".

The following lists all drugs that are currently specifically recommended for unscheduled status by NDSAC. It is not intended to reflect all drugs not otherwise captured by the Provincial Drug Schedules. **Items in BOLD UNDERLINE> are changes from the previous versions.**

### DRUG NAME

acetaminophen (in immediate release tablets, capsules, suppositories or liquid)

acetaminophen in sustained release formulations (up to and including 650 mg per unit, in package sizes containing no more than 50 units)

acetylsalicylic acid and its salts (in products for oral use in strengths of 325mg and 500mg per dosage unit)

aloin

ammonium hydroxide

attapulgit (active)

bacitracin and its salts (for topical use)

benzocaine and its salts (for topical application on the skin)

benzoyl peroxide (preparations of 5% or less as a single ingredient)

bile salts

bioflavonoids

boric acid and its salts (in ophthalmic preparations in concentrations up to and including 2%, and in contact lens solutions intended to be rinsed off prior to insertion into the eye.

brompheniramine and its salts in combination products for the relief of cough and cold symptoms

butenafine (1% cream)

camphor (in oleaginous vehicles and in liquid forms in concentrations up to and including 11%)

caprylic acid

capsaicin

casacara sagrada and its extracts and derivatives

cetirizine and its salts (in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit) in products marketed for adult use (12 years of age and older)

charcoal (activated) except for use in poisoning treatment

chloral hydrate (for topical use)

chlorpheniramine and its salts and preparations

cinnamedrine

clotrimazole and its salts (in preparations for topical use)

coal tar (in concentrations up to and including 10%)

desloratidine and its salts and preparations (in products marketed for adult use – 12 years and older)

diclofenac diethylamine in preparations for topical use on the skin in concentrations of not more than the equivalent of 1% diclofenac

digestive enzymes (from plant sources)

diphenhydramine and its salts and preparations for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of

diphenhydramine hydrochloride

docosanol 10% for topical use

docsate and its salts

famotidine and its salts, when sold in concentrations of 20mg or less of famotidine per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 600mg of famotidine

fexofenadine HCl (in products marketed for adult use – 12 years and older)

glutamic acid and its salts (gastric acidifiers)

gramicidin and its salts (for topical use)

guaifenesin

ibuprofen and its salts, when sold in strengths of 200mg or less per dosage form [Note: 200mg or less per solid form or per 5ml liquid] Applies to oral formulations only

ibuprofen and its salts in strengths over 200mg and not exceeding 400mg per oral dosage unit

inositol niacinate

ipecac and its extracts and derivatives (for use other than as an emetic)

iron and its salts and derivatives (in preparations containing 30 mg or less elemental iron per dosage unit or 5 ml oral liquid)

## DRUG NAME

ketoconazole and its salts (as a shampoo)

lidocaine and its salts (for topical use on the skin, including lozenges)

loperamide and its salts in products marketed for adult use – 12 years and older)

loratadine and its salts and preparations in products marketed for adult use (12 years of age and older)

methyl salicylate (in liquid dosage forms in concentrations up to and including 30%)

miconazole and its salts (for topical use)

naphazoline and its salts (in nasal preparations for adult use and in ophthalmic products)

naproxen sodium 220 mg per oral dosage unit (when sold in products labelled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6,600 mg)

niacin (in immediate release formulations)

niacinamide (oral)

niacinamide (for topical use)

nicotine and its salts, for human use (a) in natural substances; (b) when sold as a chewing gum containing not more than the equivalent of 4mg of nicotine per dosage unit; (c) when sold as a transdermal patch with a delivery rate of not more than the equivalent of 22mg; (d) when sold in a form to be administered orally by means of an inhalation device delivering 4mg or less of nicotine per dosage unit; or (e) when sold in a form to be administered orally as a lozenge containing 4 mg or less of nicotine per lozenge

oxiconazole (1% for topical use)

oxymetazoline (in nasal preparations for adult use and in ophthalmic products)

pancreatic enzymes, pancreatin, pancreatic lipase (except in products for the treatment of established pancreatic insufficiency)

papain (as a debriding agent)

pepsin

peptone

pheniramine

phenylephrine and its salts and preparations (for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less)

polyethylene glycol (topical administration)

polyethylene glycol 3350 as a single ingredient oral product indicated as a laxative to treat occasional constipation

polymyxin and its salts and derivatives (topical)

pramoxine and its salts for topical application on the skin and including lozenges

propylene glycol (topical application)

pyrilamine

ranitidine and its salts, when sold in concentrations of 150mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4500mg of ranitidine

salicylic acid and its salts (in topical preparations in concentrations up to and including 40%)

senna and its extracts and derivatives

sodium tartrate

tetrahydrozoline (for ophthalmic use and in nasal preparations for adults)

tioconazole and its salts (in preparations for topical use)

triethanolamine salicylate (in concentrations up to and including 20%) [trolamine]

trypsin

ubiquinone

xylometazoline and its salts (in nasal preparations for adults(0.1%))